Fortis Pharmaceuticals sp. z o.o.

Wholesale of pharmaceutical goods

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2021-09-16
Share capital
20,000.00 PLN
Activity description

Fortis Pharmaceuticals is a dynamic Polish pharmaceutical company that develops high-quality health products. It offers a range of dietary supplements such as Tribiolac, Gardipect, and Solvit D3, as well as medications including Ibufast Forte and Diclogel. The company focuses on improving patient health and comfort through its diverse product line.

Registered address
ul. Adama Mickiewicza 29, 40-085 Katowice, Poland
Email
Phone
Social media
Electronic delivery address
AE:PL-81564-40779-SUFIU-24

Financials

Revenue history (in k)

Financial insight

  • Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 – this may be an accounting template or the first year of the regime.

Filing timeliness

1 of 5 financial statements was filed late (for 2021, 80 days late).

  • 202514/07/2026
  • 202410/07/2025
  • 202303/07/2024
  • 202230/06/2023
  • 202103/10/2022
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Industry · Wholesale of pharmaceutical goods296 / 1,136
Top 26%
Division · Wholesale trade3,519 / 20,037
Top 18%
City · Katowice442 / 6,123
Top 7.2%
Voivodeship · Śląskie2,883 / 33,148
Top 8.7%
Country · Poland25,845 / 297,069
Top 8.7%

Results vs industry

Revenue
This companyUSD 6.91mMedianUSD 1.08mAverageUSD 22.54m
Net profit
This companyUSD 1.16mMedianUSD 39.26kAverageUSD 885.01k
Operating costs
This companyUSD 5.60mMedianUSD 963.92kAverageUSD 21.21m
Assets
This companyUSD 3.09mMedianUSD 610.11kAverageUSD 11.92m

Offer

Websites

Trademarks

The company holds 26 active trademarks registered with the Polish Patent Office. 1 application is pending. 2 marks have expired or were not registered. The first mark was filed in 2012.

MarkNumberClassesStatusProtected until
WITAMINA D3 FORTIS (word)Z.5765995Protected Nov 8, 2034
tadalafil fortis (word)Z.5433495Protected May 24, 2032
DEVIR (word)Z.5433455Protected May 24, 2032
Gastroprazol (word)Z.5433485Protected May 24, 2032
NEOCLIN (word)Z.5376785Protected Dec 14, 2031
MarkProtected until
WITAMINA D3 FORTIS (word)Nov 8, 2034
tadalafil fortis (word)May 24, 2032
DEVIR (word)May 24, 2032
Gastroprazol (word)May 24, 2032
NEOCLIN (word)Dec 14, 2031

Job offers

The company has its own careers page: fortispharmaceuticals.pl/pl.kariera_08c.html.

Authorized Representatives

Szymon Dawid Kamiński age 46 – President of the Management Board
Dominik Marcin Kołodziej age 45 – Vice President of the Management Board

Manner of representation

The right and obligation to represent and conduct the affairs of the transformed company shall be vested in the management board of the transformed company, acting in accordance with the rules of representation specified by the Commercial Companies Code and the articles of association of the company operating under the business name FORTIS PHARMACEUTICALS spółka z ograniczoną odpowiedzialnością with its registered office in Katowice. The management board consists of 1 to 3 members appointed by a resolution of the meeting of partners. The management board is appointed for an indefinite period; however, the partners’ resolution appointing the management board may provide otherwise. Szymon Kamiński shall be President of the Management Board of the transformed company, and Dominik Kołodziej shall be Vice-President of the Management Board.

Ownership

OwnerSharesShare valueStake
100$2,701.2450%
100$2,701.2450%

Bank accounts

Registered as a VAT taxpayer on 2012-07-18.

  • mBank
    42 1140 1049 0000 5061 7900 1002
  • mBank
    69 1140 1049 0000 5061 7900 1001
  • mBank
    15 1140 1049 0000 5061 7900 1003

Debt

No entries in the National Debtors Register (KRZ).

Public aid

26 public aid cases recorded, with a total value of $309,401.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
$21,246
De minimis aid (in accordance with Commission Regulation 2023/2831)
$1,573
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$24,756

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Aristo Pharma sp. z o.o.
Orifarm Healthcare sp. z o.o.
Biofaktor sp. z o.o.
Fatro Polska sp. z o.o.
Biovena Health sp. z o.o.
Ethifarm sp. z o.o. + limited partnership
Adpharma sp. z o.o.
Vitama S.A.
Labor Przedsiębiorstwo Farmaceutyczno - Chemiczne sp. z o.o.
Plus Solinea Pharma sp. z o.o.

FAQ

Last updated: 2026-07-17